Shopping Cart 0
Cart Subtotal
USD 0

Drug Addiction-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000

Details

Drug Addiction-Pipeline Review, H2 2017

Summary

Global Markets Direct latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction-Pipeline Review, H2 2017, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.

Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.

Report Highlights

Global Markets Direct Pharmaceutical and Healthcare latest pipeline guide Drug Addiction-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 7, 7, 1, 29, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 5 molecules, respectively.

Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Drug Addiction-Overview 7

Drug Addiction-Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 17

Drug Addiction-Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 21

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Addiction-Companies Involved in Therapeutics Development 28

Addex Therapeutics Ltd 28

Aelis Farma SAS 28

Aphios Corp 29

BioCorRx Inc 29

Cerecor Inc 30

Chiesi Farmaceutici SpA 30

Curemark LLC 31

Egalet Corp 31

Embera NeuroTherapeutics Inc 32

F. Hoffmann-La Roche Ltd 32

Foresee Pharmaceuticals LLC 33

Heptares Therapeutics Ltd 33

Immunovaccine Inc 34

Indivior Plc 34

InterveXion Therapeutics LLC 35

Intra-Cellular Therapies Inc 35

Kyorin Pharmaceutical Co Ltd 36

Kyowa Hakko Kirin Co Ltd 36

Omeros Corp 37

Opiant Pharmaceuticals Inc 37

Orexigen Therapeutics Inc 38

P2D Bioscience 38

Saniona AB 39

Stada Arzneimittel AG 39

Teva Pharmaceutical Industries Ltd 40

Zynerba Pharmaceuticals Inc 40

Drug Addiction-Drug Profiles 41

(acetaminophen + hydrocodone bitartrate + Respiratory Drug)-Drug Profile 41

(hydrocodone bitartrate + naltrexone hydrochloride)-Drug Profile 42

(metyrapone + oxazepam)-Drug Profile 43

18-MC-Drug Profile 46

ADX-71441-Drug Profile 48

ADX-71743-Drug Profile 53

ADX-88178-Drug Profile 54

AEF-0117-Drug Profile 57

ANS-6637-Drug Profile 58

AT-076-Drug Profile 59

AT-089-Drug Profile 60

AT-1001-Drug Profile 61

AT-212-Drug Profile 62

Biologic to Agonize TLR4 for Drug Addiction-Drug Profile 63

cannabidiol-Drug Profile 64

CERC-501-Drug Profile 65

CM-1212-Drug Profile 68

DDD-024-Drug Profile 69

dronabinol-Drug Profile 70

dronabinol-Drug Profile 71

Drug for Addiction-Drug Profile 72

Enzyme for Cocaine Addiction-Drug Profile 73

EORA-101-Drug Profile 74

EP-11313-Drug Profile 75

FP-004-Drug Profile 76

Gene Therapy to Activate Cocaine Hydrolase for Cocaine Abuse-Drug Profile 77

h-2E2-Drug Profile 78

ibudilast-Drug Profile 79

istradefylline-Drug Profile 89

ITI-333-Drug Profile 92

IXT-m200-Drug Profile 93

JDTic-Drug Profile 96

JQ-1-Drug Profile 97

KDAC-0001-Drug Profile 98

levofacetoperane-Drug Profile 99

lofexidine hydrochloride-Drug Profile 100

MC-100093-Drug Profile 103

naltrexone hydrochloride SR-Drug Profile 104

NLS-10-Drug Profile 106

NS-2359-Drug Profile 107

OMS-405-Drug Profile 109

OMS-527-Drug Profile 111

OPNT-001-Drug Profile 113

OREX-1019-Drug Profile 114

OREX-1038-Drug Profile 115

oxycodone hydrochloride-Drug Profile 116

RBP-8000-Drug Profile 118

Recombinant Enzyme for Cocaine Abuse-Drug Profile 120

RO-5256390-Drug Profile 121

SERx-480-Drug Profile 122

Small Molecule to Activate Kappa Opioid Receptor for CNS-Drug Profile 123

Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC-Drug Profile 124

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders-Drug Profile 125

Small Molecules for Neonatal Abstinence Syndrome-Drug Profile 126

Small Molecules to Block VMAT2 for Methamphetamine Addiction-Drug Profile 127

Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction-Drug Profile 128

Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders-Drug Profile 129

Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders-Drug Profile 130

Small Molecules to Inhibit Kappa Opioid Receptor for CNS-Drug Profile 131

Small Molecules to Scavenge Free Radicals for Oxidative Stress Related Disorders-Drug Profile 132

Small Molecules to Target 5HT2 for CNS Disorders and Obesity-Drug Profile 133

Small Molecules to Target Nicotinic Acetylcholine Receptors for Drug Addiction and Drug Abuse-Drug Profile 134

Synthetic Peptide to Target Kappa Opioid Receptors for Drug Addiction-Drug Profile 135

Vaccine for Cocaine Addiction-Drug Profile 136

Vaccine for Drug Abuse-Drug Profile 137

Vaccine for Methamphetamine Abuse-Drug Profile 138

Vaccine for Methamphetamine Addiction-Drug Profile 139

VU-0463841-Drug Profile 140

Drug Addiction-Dormant Projects 141

Drug Addiction-Discontinued Products 144

Drug Addiction-Product Development Milestones 145

Featured News & Press Releases 145

Appendix 156

Methodology 156

Coverage 156

Secondary Research 156

Primary Research 156

Expert Panel Validation 156

Contact Us 156

Disclaimer 157


List Of Figure

List of Figures

Number of Products under Development for Drug Addiction, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Drug Addiction, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Drug Addiction-Pipeline by Addex Therapeutics Ltd, H2 2017

Drug Addiction-Pipeline by Aelis Farma SAS, H2 2017

Drug Addiction-Pipeline by Aphios Corp, H2 2017

Drug Addiction-Pipeline by BioCorRx Inc, H2 2017

Drug Addiction-Pipeline by Cerecor Inc, H2 2017

Drug Addiction-Pipeline by Chiesi Farmaceutici SpA, H2 2017

Drug Addiction-Pipeline by Curemark LLC, H2 2017

Drug Addiction-Pipeline by Egalet Corp, H2 2017

Drug Addiction-Pipeline by Embera NeuroTherapeutics Inc, H2 2017

Drug Addiction-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Drug Addiction-Pipeline by Foresee Pharmaceuticals LLC, H2 2017

Drug Addiction-Pipeline by Heptares Therapeutics Ltd, H2 2017

Drug Addiction-Pipeline by Immunovaccine Inc, H2 2017

Drug Addiction-Pipeline by Indivior Plc, H2 2017

Drug Addiction-Pipeline by InterveXion Therapeutics LLC, H2 2017

Drug Addiction-Pipeline by Intra-Cellular Therapies Inc, H2 2017

Drug Addiction-Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017

Drug Addiction-Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017

Drug Addiction-Pipeline by Omeros Corp, H2 2017

Drug Addiction-Pipeline by Opiant Pharmaceuticals Inc, H2 2017

Drug Addiction-Pipeline by Orexigen Therapeutics Inc, H2 2017

Drug Addiction-Pipeline by P2D Bioscience, H2 2017

Drug Addiction-Pipeline by Saniona AB, H2 2017

Drug Addiction-Pipeline by Stada Arzneimittel AG, H2 2017

Drug Addiction-Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017

Drug Addiction-Pipeline by Zynerba Pharmaceuticals Inc, H2 2017

Drug Addiction-Dormant Projects, H2 2017

Drug Addiction-Dormant Projects, H2 2017 (Contd..1), H2 2017

Drug Addiction-Dormant Projects, H2 2017 (Contd..2), H2 2017

Drug Addiction-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Drug Addiction Therapeutic Products under Development, Key Players in Drug Addiction Therapeutics, Drug Addiction Pipeline Overview, Drug Addiction Pipeline, Drug Addiction Pipeline Assessment


Companies

Addex Therapeutics Ltd

Aelis Farma SAS

Aphios Corp

BioCorRx Inc

Cerecor Inc

Chiesi Farmaceutici SpA

Curemark LLC

Egalet Corp

Embera NeuroTherapeutics Inc

F. Hoffmann-La Roche Ltd

Foresee Pharmaceuticals LLC

Heptares Therapeutics Ltd

Immunovaccine Inc

Indivior Plc

InterveXion Therapeutics LLC

Intra-Cellular Therapies Inc

Kyorin Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

Omeros Corp

Opiant Pharmaceuticals Inc

Orexigen Therapeutics Inc

P2D Bioscience

Saniona AB

Stada Arzneimittel AG

Teva Pharmaceutical Industries Ltd

Zynerba Pharmaceuticals Inc

Company Profile

Company Profile Title

Drug Addiction-Pipeline Review, H2 2017

Summary

Global Markets Direct latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction-Pipeline Review, H2 2017, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.

Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.

Report Highlights

Global Markets Direct Pharmaceutical and Healthcare latest pipeline guide Drug Addiction-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 7, 7, 1, 29, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 5 molecules, respectively.

Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Drug Addiction-Overview 7

Drug Addiction-Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 17

Drug Addiction-Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 21

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Addiction-Companies Involved in Therapeutics Development 28

Addex Therapeutics Ltd 28

Aelis Farma SAS 28

Aphios Corp 29

BioCorRx Inc 29

Cerecor Inc 30

Chiesi Farmaceutici SpA 30

Curemark LLC 31

Egalet Corp 31

Embera NeuroTherapeutics Inc 32

F. Hoffmann-La Roche Ltd 32

Foresee Pharmaceuticals LLC 33

Heptares Therapeutics Ltd 33

Immunovaccine Inc 34

Indivior Plc 34

InterveXion Therapeutics LLC 35

Intra-Cellular Therapies Inc 35

Kyorin Pharmaceutical Co Ltd 36

Kyowa Hakko Kirin Co Ltd 36

Omeros Corp 37

Opiant Pharmaceuticals Inc 37

Orexigen Therapeutics Inc 38

P2D Bioscience 38

Saniona AB 39

Stada Arzneimittel AG 39

Teva Pharmaceutical Industries Ltd 40

Zynerba Pharmaceuticals Inc 40

Drug Addiction-Drug Profiles 41

(acetaminophen + hydrocodone bitartrate + Respiratory Drug)-Drug Profile 41

(hydrocodone bitartrate + naltrexone hydrochloride)-Drug Profile 42

(metyrapone + oxazepam)-Drug Profile 43

18-MC-Drug Profile 46

ADX-71441-Drug Profile 48

ADX-71743-Drug Profile 53

ADX-88178-Drug Profile 54

AEF-0117-Drug Profile 57

ANS-6637-Drug Profile 58

AT-076-Drug Profile 59

AT-089-Drug Profile 60

AT-1001-Drug Profile 61

AT-212-Drug Profile 62

Biologic to Agonize TLR4 for Drug Addiction-Drug Profile 63

cannabidiol-Drug Profile 64

CERC-501-Drug Profile 65

CM-1212-Drug Profile 68

DDD-024-Drug Profile 69

dronabinol-Drug Profile 70

dronabinol-Drug Profile 71

Drug for Addiction-Drug Profile 72

Enzyme for Cocaine Addiction-Drug Profile 73

EORA-101-Drug Profile 74

EP-11313-Drug Profile 75

FP-004-Drug Profile 76

Gene Therapy to Activate Cocaine Hydrolase for Cocaine Abuse-Drug Profile 77

h-2E2-Drug Profile 78

ibudilast-Drug Profile 79

istradefylline-Drug Profile 89

ITI-333-Drug Profile 92

IXT-m200-Drug Profile 93

JDTic-Drug Profile 96

JQ-1-Drug Profile 97

KDAC-0001-Drug Profile 98

levofacetoperane-Drug Profile 99

lofexidine hydrochloride-Drug Profile 100

MC-100093-Drug Profile 103

naltrexone hydrochloride SR-Drug Profile 104

NLS-10-Drug Profile 106

NS-2359-Drug Profile 107

OMS-405-Drug Profile 109

OMS-527-Drug Profile 111

OPNT-001-Drug Profile 113

OREX-1019-Drug Profile 114

OREX-1038-Drug Profile 115

oxycodone hydrochloride-Drug Profile 116

RBP-8000-Drug Profile 118

Recombinant Enzyme for Cocaine Abuse-Drug Profile 120

RO-5256390-Drug Profile 121

SERx-480-Drug Profile 122

Small Molecule to Activate Kappa Opioid Receptor for CNS-Drug Profile 123

Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC-Drug Profile 124

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders-Drug Profile 125

Small Molecules for Neonatal Abstinence Syndrome-Drug Profile 126

Small Molecules to Block VMAT2 for Methamphetamine Addiction-Drug Profile 127

Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction-Drug Profile 128

Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders-Drug Profile 129

Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders-Drug Profile 130

Small Molecules to Inhibit Kappa Opioid Receptor for CNS-Drug Profile 131

Small Molecules to Scavenge Free Radicals for Oxidative Stress Related Disorders-Drug Profile 132

Small Molecules to Target 5HT2 for CNS Disorders and Obesity-Drug Profile 133

Small Molecules to Target Nicotinic Acetylcholine Receptors for Drug Addiction and Drug Abuse-Drug Profile 134

Synthetic Peptide to Target Kappa Opioid Receptors for Drug Addiction-Drug Profile 135

Vaccine for Cocaine Addiction-Drug Profile 136

Vaccine for Drug Abuse-Drug Profile 137

Vaccine for Methamphetamine Abuse-Drug Profile 138

Vaccine for Methamphetamine Addiction-Drug Profile 139

VU-0463841-Drug Profile 140

Drug Addiction-Dormant Projects 141

Drug Addiction-Discontinued Products 144

Drug Addiction-Product Development Milestones 145

Featured News & Press Releases 145

Appendix 156

Methodology 156

Coverage 156

Secondary Research 156

Primary Research 156

Expert Panel Validation 156

Contact Us 156

Disclaimer 157


List Of Figure

List of Figures

Number of Products under Development for Drug Addiction, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Drug Addiction, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Drug Addiction-Pipeline by Addex Therapeutics Ltd, H2 2017

Drug Addiction-Pipeline by Aelis Farma SAS, H2 2017

Drug Addiction-Pipeline by Aphios Corp, H2 2017

Drug Addiction-Pipeline by BioCorRx Inc, H2 2017

Drug Addiction-Pipeline by Cerecor Inc, H2 2017

Drug Addiction-Pipeline by Chiesi Farmaceutici SpA, H2 2017

Drug Addiction-Pipeline by Curemark LLC, H2 2017

Drug Addiction-Pipeline by Egalet Corp, H2 2017

Drug Addiction-Pipeline by Embera NeuroTherapeutics Inc, H2 2017

Drug Addiction-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Drug Addiction-Pipeline by Foresee Pharmaceuticals LLC, H2 2017

Drug Addiction-Pipeline by Heptares Therapeutics Ltd, H2 2017

Drug Addiction-Pipeline by Immunovaccine Inc, H2 2017

Drug Addiction-Pipeline by Indivior Plc, H2 2017

Drug Addiction-Pipeline by InterveXion Therapeutics LLC, H2 2017

Drug Addiction-Pipeline by Intra-Cellular Therapies Inc, H2 2017

Drug Addiction-Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017

Drug Addiction-Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017

Drug Addiction-Pipeline by Omeros Corp, H2 2017

Drug Addiction-Pipeline by Opiant Pharmaceuticals Inc, H2 2017

Drug Addiction-Pipeline by Orexigen Therapeutics Inc, H2 2017

Drug Addiction-Pipeline by P2D Bioscience, H2 2017

Drug Addiction-Pipeline by Saniona AB, H2 2017

Drug Addiction-Pipeline by Stada Arzneimittel AG, H2 2017

Drug Addiction-Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017

Drug Addiction-Pipeline by Zynerba Pharmaceuticals Inc, H2 2017

Drug Addiction-Dormant Projects, H2 2017

Drug Addiction-Dormant Projects, H2 2017 (Contd..1), H2 2017

Drug Addiction-Dormant Projects, H2 2017 (Contd..2), H2 2017

Drug Addiction-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Drug Addiction Therapeutic Products under Development, Key Players in Drug Addiction Therapeutics, Drug Addiction Pipeline Overview, Drug Addiction Pipeline, Drug Addiction Pipeline Assessment


Companies

Addex Therapeutics Ltd

Aelis Farma SAS

Aphios Corp

BioCorRx Inc

Cerecor Inc

Chiesi Farmaceutici SpA

Curemark LLC

Egalet Corp

Embera NeuroTherapeutics Inc

F. Hoffmann-La Roche Ltd

Foresee Pharmaceuticals LLC

Heptares Therapeutics Ltd

Immunovaccine Inc

Indivior Plc

InterveXion Therapeutics LLC

Intra-Cellular Therapies Inc

Kyorin Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

Omeros Corp

Opiant Pharmaceuticals Inc

Orexigen Therapeutics Inc

P2D Bioscience

Saniona AB

Stada Arzneimittel AG

Teva Pharmaceutical Industries Ltd

Zynerba Pharmaceuticals Inc